Cover Image
Market Research Report

North America Lung Cancer Therapeutics Market - Industry Trends and Forecast to 2026

Published by Data Bridge Market Research Private Limited Product code 836040
Published Content info 350 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America Lung Cancer Therapeutics Market - Industry Trends and Forecast to 2026
Published: April 1, 2019 Content info: 350 Pages
Description

North America lung cancer therapeutics market is expected to grow at a healthy CAGR of 11.8% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation:

By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumors, Mediastinal Tumors, Mesothelioma, Chest Wall Tumors), Molecule Type (Small Molecules, Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Therapy Type (Single Drug Therapy, Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2026

Major growing sectors under the market segmentation are as follows:

  • On the basis of cancer type, the non-small cell lung cancer is dominating the global lung cancer therapeutics market. Lung cancer is the second most common cancer type including small cell and non-small cell lung cancer. Amongst these 80 -85% cases are non-small cell lung cancer. This type of cancer grows and spreads more slowly than small cell lung cancer and therefore it is dominating the market.
  • On the basis of molecule type, the small molecule segment is dominating the global lung cancer therapeutics market. The small molecule better effects and progression free survival of lung cancer and these agents also inhibit the growth of the metastatic cell. Due to all these reasons they are more preferred than the other types.
  • On the drug class, the alkylating drug segment is dominating the lung cancer therapeutics market. This is the first discovered drug for the treatment of cancer. Alkylating directly damage DNA and prevents the cancer cells cell division. The alkylating agent can be used in every stage of cancer. This drug shows pre and post stage. This drug also shows reduced drug accumulation and the increased detoxification.
  • On the basis of treatment type, the chemotherapy segment is dominating the lung cancer therapeutics market. Chemotherapy is a traditional process in which drugs are used to kill or inhibit cancerous cells as it is the most accepted treatment. Whereas, targeted therapy is becoming more familiar in the lung cancer sector as these classes of drugs specifically focuses on specific genetic mutations present in the tumor cells.
  • On the basis of therapy type, single drug therapy segment is dominating the lung cancer therapeutics market. The single drug therapy is the first evolved therapy used for the treatment of lung cancer. Single drug therapy is dominating the market as it is mostly preferred for the treatment of old age population, patients with poor performance status and patients who are not able to take the combination therapy. Whereas the combination drug therapy is expected to grow in future as many combination drugs are under clinical trials and is expected to launch soon. Also, few studies have shown that combination drugs can have better results as compared to the single drug therapy which will contribute to the growth of the combination therapy in the forecast period.
  • On the basis of end user, hospitals segment is dominating the lung cancer therapeutics market. The hospital segment is dominating in the lung cancer therapeutics because hospitals provides many advantages over the other segments which includes, 24 hours supportive care, immediate care for the emergency, availability of physicians, surgeons and medication.
  • On the basis of distribution channel, hospital pharmacy segment is dominating the lung cancer therapeutics market. Hospital pharmacy is dominating the global lung cancer therapeutics market as the lung cancer therapy products are prescribed based which is majorly available in hospital pharmacy.

Key Market Players:

The key market players for North America lung cancer therapeutics market are listed below:

  • Takeda Pharmaceutical Company Limited
  • ONO PHARMACEUTICAL CO., LTD.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Eli Lilly and Company
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • CELGENE CORPORATION
  • AMGEN INC.
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • ALLERGAN
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Astellas Pharma Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Others
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 RESEARCH METHODOLOGY
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7 DBMR MARKET POSITION GRID
  • 2.8 DBMR MARKET CHALLENGE MATRIX
  • 2.9 DBMR VENDOR SHARE ANALYSIS
  • 2.10 MULTIVARIATE MODELLING
  • 2.11 PRODUCT TIME LINE
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 INCREASING CASES OF LUNG CANCER
    • 3.1.2 GROWING NUMBER OF SMOKERS
    • 3.1.3 GOVERNMENT/ORGANIZATIONS FUNDING FOR THE R&D OF NEW DRUGS
    • 3.1.4 INCREASING AWARENESS
    • 3.1.5 STRATEGIC INITIATIVES OF THE COMPANIES
  • 3.2 RESTRAINS
    • 3.2.1 PRICING PRESSURE
    • 3.2.2 HIGH COST
  • 3.3 OPPORTUNITIES
    • 3.3.1 APPROVALS AND PRODUCT PIPEPLINE
    • 3.3.2 HEALTH TOURISM
    • 3.3.3 NEW PRODUCT LAUNCHES

  • 3.4 CHALLENGES
    • 3.4.1 SIDE EFFECTS
    • 3.4.2 LACK OF NUMBER OF ONCOLOGISTS
    • 3.4.3 UNMET MEDICAL NEEDS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 EPIDEMIOLOGY OF LUNG CANCER

7 REGULATORY PROCEDURE

8 PIPELINE DRUGS

9 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE

  • 9.1 OVERVIEW
  • 9.2 NON-SMALL CELL LUNG CANCER
    • 9.2.1 SQUAMOUS CELL CARCINOMA
    • 9.2.2 PULMONARY ADENOCARCINOMA
    • 9.2.3 ADENOSQUAMOUS CARCINOMA (ASC)
    • 9.2.4 LARGE CELL CARCINOMA
    • 9.2.5 SARCOMATOID CARCINOMA
    • 9.2.6 UNDIFFERENTIATED NON-SMALL CELL LUNG CANCER
    • 9.2.7 SALIVARY GLAND-TYPE LUNG CARCINOMA
      • 9.2.7.1 ADENOID CYSTIC CARCINOMA
      • 9.2.7.2 MUCOEPIDERMOID CARCINOMA
      • 9.2.7.3 ACINIC CELL CARCINOMA
      • 9.2.7.4 EPITHELIAL-MYOEPITHELIAL CARCINOMA
      • 9.2.7.5 GRANULAR CELL LUNG TUMORS
  • 9.3 METASTATIC LUNG CANCER
  • 9.4 MESOTHELIOMA
  • 9.5 CHEST WALL TUMORS
    • 9.5.1 PRIMARY TUMORS
    • 9.5.2 METASTATIC TUMORS
    • 9.5.3 SARCOMAS
  • 9.6 PULMONARY NEUROENDOCRINE TUMORS
    • 9.6.1 CARCINOID TUMORS
      • 9.6.1.1 TYPICAL CARCINOID TUMORS
      • 9.6.1.2 ATYPICAL CARCINOID TUMORS
    • 9.6.2 LARGE CELL NEUROENDOCRINE LUNGS CARCINOMA

    • 9.6.3 SMALL-CELL LUNG CANCER
      • 9.6.3.1 SMALL CELL CARCINOMA
      • 9.6.3.2 COMBINED SMALL CELL CARCINOMA
  • 9.7 MEDIASTINAL TUMORS
    • 9.7.1 GERM CELL TUMORS
    • 9.7.2 LYMPHOMAS
    • 9.7.3 THYMOMAS

10 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE

  • 10.1 OVERVIEW
  • 10.2 SMALL MOLECULE
  • 10.3 BILOGICS

11 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS

  • 11.1 OVERVIEW
  • 11.2 ALKYLATING AGENTS
  • 11.3 ANTIMETABOLITES
  • 11.4 MITOTIC INHIBITORS
  • 11.5 MULTIKINASE INHIBITORS
  • 11.6 EGFR INHIBITORS
  • 11.7 OTHERS

12 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE

  • 12.1 OVERVIEW
  • 12.2 RADIATION THERAPY
    • 12.2.1 EXTERNAL BEAM
    • 12.2.2 BRACHYTHERAPY (INTERNAL OR IMPLANT RADIATION THERAPY)
    • 12.2.3 STEREOTACTIC BODY RADIATION THERAPY (SBRT) / STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)
    • 12.2.4 STEREOTACTIC RADIOSURGERY (SRS)
  • 12.3 CHEMOTHERAPY
    • 12.3.1 CISPLATIN
    • 12.3.2 PACLITAXEL (TAXOL)
    • 12.3.3 VINORELBINE (NAVELBINE)
    • 12.3.4 DOCETAXEL (TAXOTERE)
    • 12.3.5 ALIMTA
    • 12.3.6 GEMCITABINE (GEMZAR)
    • 12.3.7 DURVALUMAB (IMFINZI)
    • 12.3.8 OTHERS

  • 12.4 TARGETED THERAPY
    • 12.4.1 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS
    • 12.4.2 ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS
    • 12.4.3 ANTI-ANGIOGENESIS THERAPY
    • 12.4.4 MONOCLONAL ANTIBODIES
    • 12.4.5 OTHERS
  • 12.5 IMMUNOTHERAPY
    • 12.5.1 ATEZOLIZUMAB (TECENTRIQ)
    • 12.5.2 DURVALUMAB (IMFINZI)
    • 12.5.3 NIVOLUMAB (OPDIVO)
    • 12.5.4 PEMBROLIZUMAB (KEYTRUDA)
  • 12.6 OTHERS

13 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE

  • 13.1 OVERVIEW
  • 13.2 SINGLE DRUG THERAPY
  • 13.3 COMBINATION THERAPY

14 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 SPECIALTY CLINICS
  • 14.4 HOMECARE
  • 14.5 OTHERS

15 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 HOSPITAL PHARMACY
  • 15.3 RETAIL PHARMACY
  • 15.4 ONLINE
  • 15.5 OTHERS

16 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

  • 16.1 NORTH AMERICA
    • 16.1.1 U.S.
    • 16.1.2 CANADA
    • 16.1.3 MEXICO

17 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

18 COMPANY PROFILES

  • 18.1 F. HOFFMANN-LA ROCHE LTD
    • 18.1.1 COMPANY SNAPSHOT
    • 18.1.2 REVENUE ANALYSIS
    • 18.1.3 GEOGRAPHICAL PRESENCE
    • 18.1.4 COMPANY SHARE ANALYSIS
    • 18.1.5 PRODUCT PORTFOLIO
    • 18.1.6 RECENT DEVELOPMENTS
  • 18.2 MERCK & CO., INC.
    • 18.2.1 COMPANY OVERVIEW
    • 18.2.2 REVENUE ANALYSIS
    • 18.2.3 GEOGRAPHICAL PRESENCE
    • 18.2.4 COMPANY SHARE ANALYSIS
    • 18.2.5 PRODUCT PORTFOLIO
    • 18.2.6 RECENT DEVELOPMENTS
  • 18.3 BRISTOL-MYERS SQUIBB COMPANY
    • 18.3.1 COMPANY OVERVIEW
    • 18.3.2 REVENUE ANALYSIS
    • 18.3.3 GEOGRAPHICAL PRESENCE
    • 18.3.4 COMPANY SHARE ANALYSIS
    • 18.3.5 PRODUCT PORTFOLIO
    • 18.3.6 RECENT DEVELOPMENTS
  • 18.4 ASTRAZENECA
    • 18.4.1 COMPANY SNAPSHOT
    • 18.4.2 REVENUE ANALYSIS
    • 18.4.3 GEOGRAPHICAL PRESENCE
    • 18.4.4 COMPANY SHARE ANALYSIS
    • 18.4.5 PRODUCT PORTFOLIO
    • 18.4.6 RECENT DEVELOPMENTS
  • 18.5 ELI LILLY AND COMPANY
    • 18.5.1 COMPANY SNAPSHOT
    • 18.5.2 REVENUE ANALYSIS
    • 18.5.3 GEOGRAPHICAL PRESENCE
    • 18.5.4 COMPANY SHARE ANALYSIS
    • 18.5.5 PRODUCT PORTFOLIO
    • 18.5.6 RECENT DEVELOPMENTS
  • 18.6 ALLERGAN
    • 18.6.1 COMPANY OVERVIEW
    • 18.6.2 REVENUE ANALYSIS
    • 18.6.3 GEOGRAPHICAL PRESENCE
    • 18.6.4 PRODUCT PORTFOLIO
    • 18.6.5 RECENT DEVELOPMENTS
  • 18.7 AMGEN INC.
    • 18.7.1 COMPANY OVERVIEW
    • 18.7.2 REVENUE ANALYSIS
    • 18.7.3 GEOGRAPHICAL PRESENCE
    • 18.7.4 PRODUCT PORTFOLIO
    • 18.7.5 RECENT DEVELOPMENTS
  • 18.8 ASTELLAS PHARMA INC.
    • 18.8.1 COMPANY OVERVIEW
    • 18.8.2 REVENUE ANALYSIS
    • 18.8.3 GEOGRAPHICAL PRESENCE
    • 18.8.4 PRODUCT PORTFOLIO
    • 18.8.5 RECENT DEVELOPMENTS
  • 18.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 18.9.1 COMPANY OVERVIEW
    • 18.9.2 REVENUE ANALYSIS
    • 18.9.3 GEOGRAPHICAL PRESENCE
    • 18.9.4 PRODUCT PORTFOLIO
    • 18.9.5 RECENT DEVELOPMENTS
  • 18.10 CELGENE CORPORATION
    • 18.10.1 COMPANY OVERVIEW
    • 18.10.2 REVENUE ANALYSIS
    • 18.10.3 GEOGRAPHICAL PRESENCE
    • 18.10.4 PRODUCT PORTFOLIO
    • 18.10.5 RECENT DEVELOPMENTS
  • 18.11 DR. REDDY'S LABORATORIES LTD.
    • 18.11.1 COMPANY SNAPSHOT
    • 18.11.2 REVENUE ANALYSIS
    • 18.11.3 GEOGRAPHICAL PRESENCE
    • 18.11.4 PRODUCT PORTFOLIO
    • 18.11.5 RECENT DEVELOPMENTS

  • 18.12 GLAXOSMITHKLINE PLC.
    • 18.12.1 COMPANY OVERVIEW
    • 18.12.2 REVENUE ANALYSIS
    • 18.12.3 GEOGRAPHICAL PRESENCE
    • 18.12.4 PRODUCT PORTFOLIO
    • 18.12.5 RECENT DEVELOPMENTS
  • 18.13 JOHNSON & JOHNSON SERVICES, INC.
    • 18.13.1 COMPANY SNAPSHOT
    • 18.13.2 REVENUE ANALYSIS
    • 18.13.3 GEOGRAPHICAL PRESENCE
    • 18.13.4 PRODUCT PORTFOLIO
    • 18.13.5 RECENT DEVELOPMENTS
  • 18.14 NOVARTIS AG
    • 18.14.1 COMPANY SNAPSHOT
    • 18.14.2 REVENUE ANALYSIS
    • 18.14.3 GEOGRAPHICAL PRESENCE
    • 18.14.4 PRODUCT PORTFOLIO
    • 18.14.5 RECENT DEVELOPMENT
  • 18.15 ONO PHARMACEUTICAL CO., LTD.
    • 18.15.1 COMPANY OVERVIEW
    • 18.15.2 REVENUE ANALYSIS
    • 18.15.3 GEOGRAPHICAL PRESENCE
    • 18.15.4 PRODUCT PORTFOLIO
    • 18.15.5 RECENT DEVELOPMENTS
  • 18.16 PFIZER INC.
    • 18.16.1 COMPANY SNAPSHOT
    • 18.16.2 RECENT FINANCIALS
    • 18.16.3 GEOGRAPHICAL PRESENCE
    • 18.16.4 PRODUCT PORTFOLIO
    • 18.16.5 RECENT DEVELOPMENTS
  • 18.17 SANOFI
    • 18.17.1 COMPANY OVERVIEW
    • 18.17.2 REVENUE ANALYSIS
    • 18.17.3 GEOGRAPHICAL PRESENCE
    • 18.17.4 PRODUCT PORTFOLIO
    • 18.17.5 RECENT DEVELOPMENTS

  • 18.18 SUMITOMO DAINIPPON PHARMA CO., LTD.
    • 18.18.1 COMPANY OVERVIEW
    • 18.18.2 REVENUE ANALYSIS
    • 18.18.3 GEOGRAPHICAL PRESENCE
    • 18.18.4 PRODUCT PORTFOLIO
    • 18.18.5 RECENT DEVELOPMENTS
  • 18.19 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 18.19.1 COMPANY SNAPSHOT
    • 18.19.2 REVENUE ANALYSIS
    • 18.19.3 GEOGRAPHICAL PRESENCE
    • 18.19.4 PRODUCT PORTFOLIO
    • 18.19.5 RECENT DEVELOPMENTS
  • 18.20 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 18.20.1 COMPANY OVERVIEW
    • 18.20.2 REVENUE ANALYSIS
    • 18.20.3 GEOGRAPHICAL PRESENCE
    • 18.20.4 PRODUCT PORTFOLIO
    • 18.20.5 RECENT DEVELOPMENTS
  • 18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 18.21.1 COMPANY OVERVIEW
    • 18.21.2 REVENUE ANALYSIS
    • 18.21.3 GEOGRAPHICAL PRESENCE
    • 18.21.4 PRODUCT PORTFOLIO
    • 18.21.5 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 PREVALENCE OF SUBTYPES OF LUNG CARCINOMA IN SMOKERS AND NEVER-SMOKERS
  • TABLE 2 COST OF TARGETED THERAPIES FOR THE TREATMENT OF NSCLC (2018)
  • TABLE 3 COST OF IMMUNOTHERAPIES FOR THE TREATMENT OF NSCLC (2018)

TABLE 4 SOME OF THE PIPELINE LUNG CANCER DRUGS ARE MENTIONED IN THE BELOW TABLE:

  • TABLE 5 AVERAGE COST OF LUNG CANCER TREATMENT (2018)
  • TABLE 6 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 7 NORTH AMERICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 8 NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 9 NORTH AMERICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 10 NORTH AMERICA METASTATIC LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 11 NORTH AMERICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 12 NORTH AMERICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 13 NORTH AMERICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 14 NORTH AMERICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 15 NORTH AMERICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 16 NORTH AMERICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 17 NORTH AMERICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 18 NORTH AMERICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 19 NORTH AMERICA MESOTHELIOMA IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 20 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 21 NORTH AMERICA SMALL MOLECULE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 22 NORTH AMERICA BIOLOGICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 23 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 24 NORTH AMERICA ALKYLATING AGENTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 25 NORTH AMERICA ANTIMETABOLITES IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 26 NORTH AMERICA MITOTIC INHIBITORS PRODUCTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 27 NORTH AMERICA MULTIKINASE INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 28 NORTH AMERICA EGFR INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 29 NORTH AMERICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 30 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 31 NORTH AMERICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 32 NORTH AMERICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 33 NORTH AMERICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 34 NORTH AMERICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 35 NORTH AMERICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 36 NORTH AMERICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 37 NORTH AMERICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 38 NORTH AMERICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 39 NORTH AMERICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 40 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 41 NORTH AMERICA SINGLE DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 42 NORTH AMERICA COMBINATION DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 43 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 44 NORTH AMERICA HOSPITALS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 45 NORTH AMERICA SPECIALTY CLINICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 46 NORTH AMERICA HOMECARE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 47 NORTH AMERICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 48 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 49 NORTH AMERICA HOSPITAL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 50 NORTH AMERICA RETAIL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 51 NORTH AMERICA ONLINE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 52 NORTH AMERICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 53 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 54 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 55 NORTH AMERICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 56 NORTH AMERICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 57 NORTH AMERICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)T
  • TABLE 58 NORTH AMERICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 59 NORTH AMERICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 60 NORTH AMERICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 61 NORTH AMERICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 62 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 63 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 64 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 65 NORTH AMERICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 66 NORTH AMERICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 67 NORTH AMERICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 68 NORTH AMERICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 69 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 70 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 71 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 72 U.S LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 73 U.S. NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 74 U.S SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 75 U.S CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 76 U.S PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 77 U.S SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 78 U.S. CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 79 U.S. MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION))
  • TABLE 80 U.S LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 81 U.S LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 82 U.S LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 83 U.S LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 84 U.S RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 85 U.S TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 86 U.S IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 87 U.S LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 88 U.S LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 89 U.S LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 90 CANADA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 91 CANADA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 92 CANADA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 93 CANADA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 94 CANADA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 95 CANADA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 96 CANADA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 97 CANADA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 98 CANADA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 99 CANADA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 100 CANADA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 101 CANADA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 102 CANADA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 103 CANADA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 104 CANADA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 105 CANADA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 106 CANADA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 107 CANADA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 108 MEXICO LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 109 MEXICO NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 110 MEXICO SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 111 MEXICO CHEST WALL TUMORS LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 112 MEXICO PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 113 MEXICO SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 114 MEXICO CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 115 MEXICO MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 116 MEXICO SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 117 MEXICO LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 118 MEXICO LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 119 MEXICO CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 120 MEXICO RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 121 MEXICO TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 122 MEXICO IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 123 MEXICO LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 124 MEXICO LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 125 MEXICO LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: SEGMENTATION
  • FIGURE 2 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: DATA VALIDATION MODEL
  • FIGURE 3 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: DROC ANALYSIS
  • FIGURE 4 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: THE MARKET CHALLENGE MATRIX
  • FIGURE 9 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: DBMR VENDOR SHARE ANALYSIS
  • FIGURE 10 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET
  • FIGURE 11 COUNTRY WISE LUNG CANCER RATES IN 2018
  • FIGURE 12 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE LUNG CANCER THERAPEUTICS MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2019 TO 2026
  • FIGURE 13 INCREASING CASES OF LUNG CANCER, GROWING NUMBER OF SMOKERS AND RISING GOVERNMENT INITIATIVES ARE EXPECTED TO DRIVE THE NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET IN THE FORECAST PERIOD 2019 TO 2026
  • FIGURE 14 NON-SMALL CELL LUNG CANCER IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET IN 2019 & 2026
  • FIGURE 15 WORLDWIDE LUNG CANCER INCIDENCE (2018)
  • FIGURE 16 WORLDWIDE PREVALENCE OF LUNG CANCER FOR LAST 5 YEARS
  • FIGURE 17 WORLDWIDE MORTALITY RATE OF LUNG CANCER (2018)
  • FIGURE 18 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE, 2018
  • FIGURE 19 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY MOLECULE TYPE, 2018
  • FIGURE 20 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY DRUG CLASS, 2018
  • FIGURE 21 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY TREATMENT TYPE, 2018
  • FIGURE 22 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY THERAPY TYPE, 2018
  • FIGURE 23 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY END USER, 2018
  • FIGURE 24 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, 2018
  • FIGURE 25 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 26 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 27 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 28 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 29 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE (2019-2026)
  • FIGURE 30 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)
Back to Top